argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
American Uranium's Lo Herma Resource Reaches 9.96Mlbs as Indicated Resources Grow 72% Prior to Publication of Planned Scoping Study
Angkor Resources' Subsidiary Meets with Cambodian National Refinery Systems to Discuss Potential In-Country Offtake for Block VIII Production
Noble Acquires North Bradshaw Property in Northern Ontario and Provides Final Information on Arrangement
